CG
ADPT icon

Cutler Group’s Adaptive Biotechnologies ADPT Stock Holding History

Cutler Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-800
Closed -$4K – 4725
2020
Q3 		$4K Sell
800
-4,900
-86% -$206K ﹤0.01% 3594
2020
Q2 		$76K Buy
5,700
+600
+12% +$21.9K 0.01% 1465
2020
Q1 		$10K Buy
+5,100
New +$142K ﹤0.01% 2698

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's ADPT Position: Q3 2022 in Review

Cutler Group sold out of Adaptive Biotechnologies (ADPT) in Q3 2022, closing a stake of 800 shares — an estimated $6K sold.

Cutler Group first reported a position in ADPT in Q3 2019 and held it in 8 quarters. The position peaked at $28K in Q2 2021. 226 funds tracked by Wall St. Rank hold ADPT as of Q3 2022.

  • Cutler Group reported no remaining Adaptive Biotechnologies position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 800 Adaptive Biotechnologies shares in Q3 2022, an estimated $6K.
  • Cutler Group first reported a position in Adaptive Biotechnologies in Q3 2019 and held it in 8 quarters.
  • Cutler Group's Adaptive Biotechnologies position peaked at $28K in Q2 2021.
  • 226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.